Literature DB >> 14601523

Non-primate lentiviral vectors.

Eric M Poeschla1.   

Abstract

Feline and equine lentivirus-derived vector systems are yielding impressive preclinical results in tissue culture, animal and ex vivo human organ models. Improved basic scientific understanding of lentiviral life cycles is facilitating development of these vectors, and initial systems based on other lentiviruses have been constructed. In addition to further engineering of the individual platforms for safety and efficacy, important goals for the field are to compare different lentiviral vector systems rigorously in specific human targets, and to derive clinical grade packaging/producer cell lines. Further progress in fundamental virology will be critical. Species-specific lentiviral restriction has recently emerged as a dynamic subject relevant to lentiviral pathogenesis research and lentiviral vector-based gene therapy. This review summarizes recent results in this growing field and discusses elements of an agenda for furthering application of these vectors to human gene therapy.

Entities:  

Mesh:

Year:  2003        PMID: 14601523

Source DB:  PubMed          Journal:  Curr Opin Mol Ther        ISSN: 1464-8431


  11 in total

Review 1.  Lentiviral transgenesis.

Authors:  Alexander Pfeifer
Journal:  Transgenic Res       Date:  2004-12       Impact factor: 2.788

2.  Mobilization and mechanism of transcription of integrated self-inactivating lentiviral vectors.

Authors:  Hideki Hanawa; Derek A Persons; Arthur W Nienhuis
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

3.  Restriction of feline immunodeficiency virus by Ref1, Lv1, and primate TRIM5alpha proteins.

Authors:  Dyana T Saenz; Wulin Teo; John C Olsen; Eric M Poeschla
Journal:  J Virol       Date:  2005-12       Impact factor: 5.103

4.  Nanomaterials in controlled drug release.

Authors:  Xin-Jun Cai; Ying-Ying Xu
Journal:  Cytotechnology       Date:  2011-07-01       Impact factor: 2.058

5.  Design and in vivo characterization of self-inactivating human and non-human lentiviral expression vectors engineered for streptogramin-adjustable transgene expression.

Authors:  Barbara Mitta; Cornelia C Weber; Markus Rimann; Martin Fussenegger
Journal:  Nucleic Acids Res       Date:  2004-07-16       Impact factor: 16.971

Review 6.  Human gene therapy vectors derived from feline lentiviruses.

Authors:  Román A Barraza; Eric M Poeschla
Journal:  Vet Immunol Immunopathol       Date:  2008-01-19       Impact factor: 2.046

Review 7.  Intensive RNAi with lentiviral vectors in mammalian cells.

Authors:  Tanner Miest; Dyana Saenz; Anne Meehan; Manuel Llano; Eric M Poeschla
Journal:  Methods       Date:  2008-11-28       Impact factor: 3.608

8.  RNAi screen identifies UBE2D3 as a mediator of all-trans retinoic acid-induced cell growth arrest in human acute promyelocytic NB4 cells.

Authors:  Hidenori Hattori; Xueqing Zhang; Yonghui Jia; Kulandayan K Subramanian; Hakryul Jo; Fabien Loison; Peter E Newburger; Hongbo R Luo
Journal:  Blood       Date:  2007-04-09       Impact factor: 22.113

9.  Gene therapy: a potential approach for cancer pain.

Authors:  Chalonda R Handy; Christina Krudy; Nicholas Boulis
Journal:  Pain Res Treat       Date:  2011-06-09

10.  The polyamidoamine-mediated inhibition of bcl-2 by small hairpin RNA to induce apoptosis in human lens epithelial cells.

Authors:  Xin-Hua Wu; Yi Lu; Yan-Wen Fang; Yong-Xiang Jiang
Journal:  Mol Vis       Date:  2012-01-12       Impact factor: 2.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.